NTLA earnings: next report 2026-08-06, real EPS beat/miss history, analyst consensus Buy, P/E -3.14. Updated 2026-07-23.
Intellia Therapeutics (NTLA) Research Hub
Intellia Therapeutics (NTLA) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 11.74 USD (-3.85%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -3.14, market cap 1.25B. This hub links to the full technical, earnings and options research available for NTLA.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 11.74 USD (-3.85%) |
| 52-week range | 10.15 USD – 18.48 USD |
| Trend regime | Range |
| 14-day RSI | 47.9 (Neutral) |
| Trailing P/E | -3.14 |
| Market cap | 1.25B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-06 |
Available research for NTLA
Covered Call on NTLA: how it works, illustrative setup around the real 11.74 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on NTLA: how it works, illustrative setup around the real 11.74 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on NTLA: how it works, illustrative setup around the real 11.74 USD price, max profit/loss, breakeven and when to use it. Educational.
NTLA technical analysis: range, last 11.74 USD, RSI 47.9, 52w range 10.15 USD–18.48 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is NTLA in?
Intellia Therapeutics (NTLA) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is NTLA in an uptrend or downtrend?
As of 2026-09-11, NTLA is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is NTLA's trailing P/E ratio?
NTLA's trailing P/E is -3.14, with a market cap of 1.25B. See the earnings research page for full valuation detail.
When does NTLA next report earnings?
NTLA is next scheduled to report earnings on 2026-08-06, with a consensus EPS estimate of -0.8 USD.